JP2018520091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520091A5 JP2018520091A5 JP2017557287A JP2017557287A JP2018520091A5 JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5 JP 2017557287 A JP2017557287 A JP 2017557287A JP 2017557287 A JP2017557287 A JP 2017557287A JP 2018520091 A5 JP2018520091 A5 JP 2018520091A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- activatable antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022910A JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156835P | 2015-05-04 | 2015-05-04 | |
| US62/156,835 | 2015-05-04 | ||
| US201562220805P | 2015-09-18 | 2015-09-18 | |
| US62/220,805 | 2015-09-18 | ||
| PCT/US2016/030785 WO2016179285A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Division JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520091A JP2018520091A (ja) | 2018-07-26 |
| JP2018520091A5 true JP2018520091A5 (enExample) | 2019-06-20 |
| JP7028648B2 JP7028648B2 (ja) | 2022-03-02 |
Family
ID=55967468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557287A Expired - Fee Related JP7028648B2 (ja) | 2015-05-04 | 2016-05-04 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022910A Withdrawn JP2022065115A (ja) | 2015-05-04 | 2022-02-17 | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10745481B2 (enExample) |
| EP (2) | EP3292150B1 (enExample) |
| JP (2) | JP7028648B2 (enExample) |
| KR (1) | KR20180010203A (enExample) |
| CN (2) | CN115340607A (enExample) |
| AU (1) | AU2016257929B2 (enExample) |
| BR (1) | BR112017023872A2 (enExample) |
| CA (1) | CA2984948A1 (enExample) |
| DK (1) | DK3292150T3 (enExample) |
| EA (1) | EA201792414A1 (enExample) |
| ES (1) | ES2796698T3 (enExample) |
| HR (1) | HRP20200721T1 (enExample) |
| HU (1) | HUE049866T2 (enExample) |
| IL (2) | IL292798A (enExample) |
| MX (2) | MX388350B (enExample) |
| PL (1) | PL3292150T3 (enExample) |
| PT (1) | PT3292150T (enExample) |
| RS (1) | RS60222B1 (enExample) |
| SG (2) | SG10202110908WA (enExample) |
| WO (1) | WO2016179285A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11089959B2 (en) | 2013-03-15 | 2021-08-17 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| US9782075B2 (en) | 2013-03-15 | 2017-10-10 | I2Dx, Inc. | Electronic delivery of information in personalized medicine |
| CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| KR102790260B1 (ko) | 2013-09-25 | 2025-04-01 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| US9562073B2 (en) | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| MX388350B (es) | 2015-05-04 | 2025-03-19 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| MX2019005756A (es) | 2016-11-28 | 2019-08-14 | Chugai Pharmaceutical Co Ltd | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
| AU2017364818C1 (en) | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| JP2020500900A (ja) | 2016-12-09 | 2020-01-16 | シアトル ジェネティクス インコーポレーテッド | コイルドコイルでマスキングされた二価抗体 |
| US11220544B2 (en) * | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| JP2020531430A (ja) | 2017-08-16 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| AU2018324097A1 (en) * | 2017-08-30 | 2020-03-12 | Cytomx Therapeutics, Inc. | Activatable anti-CD166 antibodies and methods of use thereof |
| AU2018328291B2 (en) * | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2019051122A2 (en) * | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS |
| MX2020005160A (es) | 2017-11-28 | 2020-08-20 | Chugai Pharmaceutical Co Ltd | Molecula de union a ligando que tiene actividad de union a ligando ajustable. |
| CA3083259A1 (en) | 2017-11-28 | 2019-06-06 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide including antigen-binding domain and carrying section |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| MX2020012248A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| JPWO2019230868A1 (ja) | 2018-05-30 | 2021-06-24 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| WO2020092881A1 (en) | 2018-11-02 | 2020-05-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| CN120248140A (zh) | 2018-12-06 | 2025-07-04 | 西托姆克斯治疗公司 | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 |
| US20220089752A1 (en) * | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2020176672A1 (en) * | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN113631194A (zh) | 2019-03-21 | 2021-11-09 | 伊缪诺金公司 | 制备细胞结合剂-药物缀合物的方法 |
| KR102212149B1 (ko) * | 2019-03-28 | 2021-02-04 | 부산대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 압타머 및 이의 용도 |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| US20220226514A1 (en) * | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| US20220324975A1 (en) | 2019-06-05 | 2022-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody cleavage site binding molecule |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114650844A (zh) * | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | 抗cd47抗体、可活化抗cd47抗体及其使用方法 |
| EP4058471A1 (en) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JP2023521384A (ja) | 2020-04-09 | 2023-05-24 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗体を含む組成物 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| US20240000960A1 (en) * | 2020-11-16 | 2024-01-04 | The Cleveland Clinic Foundation | Anti-cd6 antibody conjugates for treating t-cell mediated disorders and t-cell lymphoma/leukemia |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| EP4416178A1 (en) | 2021-10-15 | 2024-08-21 | CytomX Therapeutics, Inc. | Activatable polypeptide complex |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250011422A1 (en) * | 2021-11-12 | 2025-01-09 | University Of Florida Research Foundation, Incorporated | Siglec-6 antibodies, derivative compounds and related uses |
| CN114621348B (zh) * | 2022-01-24 | 2023-09-22 | 深圳市乐土生物医药有限公司 | 一种多肽及其抗磷脂酰肌醇蛋白聚糖3抗体 |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| CN119300859A (zh) | 2022-04-01 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活多特异性分子和其使用方法 |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023222580A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| EP4554625A1 (en) | 2022-07-12 | 2025-05-21 | CytomX Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
| WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| KR20250034273A9 (ko) * | 2023-08-28 | 2025-12-29 | 파로스젠 주식회사 | 항-도펠 항체-약물 접합체 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| WO1999011287A1 (en) | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| CA2483912A1 (en) | 2002-05-03 | 2003-11-13 | Raven Biotechnologies, Inc. | Alcam and alcam modulators |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| ATE440866T1 (de) | 2003-12-22 | 2009-09-15 | Glaxo Group Ltd | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten |
| EP1930346B1 (en) | 2005-08-29 | 2011-10-19 | Japan Science and Technology Agency | Antibody produced using ostrich and method for production thereof |
| CA2620886C (en) | 2005-08-31 | 2017-03-14 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| US7582441B1 (en) | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
| JP5612247B2 (ja) | 2005-11-29 | 2014-10-22 | 独立行政法人科学技術振興機構 | Ｃｄ１６６に対するモノクローナル抗体およびその産生方法 |
| WO2007105027A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| GB0705775D0 (en) | 2007-03-26 | 2007-05-02 | Affitech As | Product |
| JP2009055899A (ja) | 2007-08-07 | 2009-03-19 | Igaku Seibutsugaku Kenkyusho:Kk | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| CN101970494B (zh) | 2008-02-20 | 2015-01-21 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| EP2388320B1 (en) | 2008-12-22 | 2017-02-15 | Chugai Seiyaku Kabushiki Kaisha | Anti-hs6st2 antibodies and uses thereof |
| AU2010203353B2 (en) | 2009-01-12 | 2016-06-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
| EP2419447B1 (en) | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| WO2010129609A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| JP2013542958A (ja) | 2010-11-03 | 2013-11-28 | イミュノジェン・インコーポレーテッド | アンサマイトシン誘導体を含む細胞傷害性剤 |
| US20140199233A1 (en) | 2011-05-11 | 2014-07-17 | The Regents Of The University Of California | Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor |
| SI2817338T1 (sl) * | 2012-02-24 | 2017-11-30 | Abbvie Stemcentrx Llc | Modulatorji DLL3 in postopki uporabe |
| RU2713121C2 (ru) * | 2012-04-27 | 2020-02-03 | Сайтомкс Терапьютикс, Инк. | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| WO2014107599A2 (en) | 2013-01-04 | 2014-07-10 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
| CN116063479A (zh) * | 2013-06-04 | 2023-05-05 | 西托姆克斯治疗公司 | 用于缀合可活化抗体的组合物和方法 |
| CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| MX388350B (es) | 2015-05-04 | 2025-03-19 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos. |
| WO2017015227A1 (en) | 2015-07-17 | 2017-01-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating cd166-expressing cancer |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CN109311992B (zh) | 2016-06-15 | 2022-10-18 | 克利夫兰临床基金会 | 用于治疗t细胞介导疾病的新型抗cd6抗体 |
| JP6183523B2 (ja) | 2016-09-14 | 2017-08-23 | 株式会社アンセイ | 車両用開閉体の開閉装置及び車両用開閉体の開閉装置用リンク機構 |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| WO2018071058A1 (en) | 2016-10-15 | 2018-04-19 | Baylor College Of Medicine | Platform for enhanced targeted cell delivery |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| AU2018324097A1 (en) | 2017-08-30 | 2020-03-12 | Cytomx Therapeutics, Inc. | Activatable anti-CD166 antibodies and methods of use thereof |
| WO2020092881A1 (en) | 2018-11-02 | 2020-05-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| WO2020176672A1 (en) | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
-
2016
- 2016-05-04 MX MX2017014136A patent/MX388350B/es unknown
- 2016-05-04 BR BR112017023872A patent/BR112017023872A2/pt not_active IP Right Cessation
- 2016-05-04 EP EP16722502.8A patent/EP3292150B1/en active Active
- 2016-05-04 CN CN202210950237.0A patent/CN115340607A/zh active Pending
- 2016-05-04 IL IL292798A patent/IL292798A/en unknown
- 2016-05-04 AU AU2016257929A patent/AU2016257929B2/en not_active Expired - Fee Related
- 2016-05-04 PL PL16722502T patent/PL3292150T3/pl unknown
- 2016-05-04 WO PCT/US2016/030785 patent/WO2016179285A1/en not_active Ceased
- 2016-05-04 EP EP20155149.6A patent/EP3708585A1/en not_active Withdrawn
- 2016-05-04 HU HUE16722502A patent/HUE049866T2/hu unknown
- 2016-05-04 HR HRP20200721TT patent/HRP20200721T1/hr unknown
- 2016-05-04 PT PT167225028T patent/PT3292150T/pt unknown
- 2016-05-04 RS RS20200511A patent/RS60222B1/sr unknown
- 2016-05-04 SG SG10202110908WA patent/SG10202110908WA/en unknown
- 2016-05-04 CA CA2984948A patent/CA2984948A1/en active Pending
- 2016-05-04 US US15/146,603 patent/US10745481B2/en active Active
- 2016-05-04 SG SG10201913767VA patent/SG10201913767VA/en unknown
- 2016-05-04 CN CN201680038634.3A patent/CN107849133B/zh not_active Expired - Fee Related
- 2016-05-04 DK DK16722502.8T patent/DK3292150T3/da active
- 2016-05-04 JP JP2017557287A patent/JP7028648B2/ja not_active Expired - Fee Related
- 2016-05-04 KR KR1020177034835A patent/KR20180010203A/ko not_active Abandoned
- 2016-05-04 ES ES16722502T patent/ES2796698T3/es active Active
- 2016-05-04 EA EA201792414A patent/EA201792414A1/ru unknown
-
2017
- 2017-11-02 IL IL255414A patent/IL255414B/en unknown
- 2017-11-03 MX MX2021014735A patent/MX2021014735A/es unknown
-
2019
- 2019-12-20 US US16/723,809 patent/US11753466B2/en active Active
-
2022
- 2022-02-17 JP JP2022022910A patent/JP2022065115A/ja not_active Withdrawn
-
2023
- 2023-07-18 US US18/354,353 patent/US20240076374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520091A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| EP3292149B1 (en) | Activatable anti-cd71 antibodies, and methods of use thereof | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| JP2017522871A5 (enExample) | ||
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2018516539A (ja) | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 | |
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| JP7547205B2 (ja) | 抗ｈｅｒ２バイパラトピック抗体－薬物コンジュゲート及び使用方法 | |
| CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| CN105288644A (zh) | 抗体-药物缀合物 | |
| Zhang et al. | Novel development strategies and challenges for anti-Her2 antibody-drug conjugates | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| Jin et al. | An anti-EGFR× cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations | |
| Chen et al. | Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG× CD20) | |
| CN112175082B (zh) | 抗叶酸受体α抗体、其缀合物及其用途 | |
| CN111278462A (zh) | 抗egfr抗体药物结合物(adc)和其用途 | |
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム | |
| JPWO2021251459A5 (enExample) | ||
| Zhong et al. | A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| AU2018285523A1 (en) | Antibody drug conjugates that bind LGR5 | |
| JPWO2020176497A5 (enExample) |